There have been quite a lot of notable developments for sufferers with kidney most cancers on the symposium: © SciePro – inventory.adobe.com
On the 2025 American Society of Medical Oncology (ASCO) Genitourinary Cancers Symposium, there have been quite a lot of notable developments for sufferers with kidney most cancers, Dr. Emre Yekedüz defined in an interview with CURE.
Yekedüz is a medical oncologist and analysis fellow in medication at Dana-Farber Most cancers Institute in Boston.
CURE: What have been crucial takeaways from the symposium concerning kidney most cancers remedy?
Yekedüz: I can title the three most essential key takeaways for our sufferers from the ASCO GU 2025 symposium. The primary promising development is the mixture routine of Lenvima (lenvatinib), a tyrosine kinase inhibitor utilized in kidney most cancers sufferers, and Welireg (belzutifan), a HIF-2α inhibitor additionally utilized in kidney most cancers. This mix exhibits promise in second-line remedy and past for sufferers with metastatic clear cell RCC.
The second development is KIM-1, the kidney harm molecule-1, a promising biomarker for evaluating prognosis and predicting survival in metastatic clear cell RCC sufferers receiving Opdivo (nivolumab) plus Yervoy (ipilimumab). These are the immune checkpoint inhibitors utilized in our kidney most cancers sufferers.
The third is a novel HIF-2α inhibitor, a goal for kidney most cancers sufferers. Casdatifan is at present beneath growth. An early part 1 trial, offered by Dr. Toni Choueiri, confirmed a 30% goal response fee as a single agent in second-line remedy and past for sufferers with metastatic clear cell renal cell carcinoma (RCC). We are actually awaiting different combos in part 3 trials. This can be a novel and promising agent for our kidney most cancers sufferers.
Glossary
Goal response fee: sufferers who responded partially or fully to remedy.
Full response: the disappearance of most cancers.
Have been there any important developments in focused therapies or immunotherapy for kidney most cancers offered on the symposium?
The primary promising growth is the Lenvima plus Welireg mixture. Lenvima is a tyrosine kinase inhibitor, and Welireg is a HIF-2α inhibitor. This mix has a 47% goal response fee in a part 2 trial, suggesting it is a promising remedy for beforehand handled metastatic clear cell RCC sufferers. Based mostly on these outcomes, we’re awaiting the LITESPARK-011 trial. This part 3 trial compares the Lenvima plus Welireg mixture versus Cabometyx (cabozantinib), one other tyrosine kinase inhibitor, in beforehand handled metastatic clear cell RCC sufferers. We’re very enthusiastic about this mix for our sufferers.
The second development is Lenvima, the tyrosine kinase inhibitor, plus Tevimbra (tislelizumab), an immune checkpoint inhibitor. This mix is being explored in fumarate hydratase-deficient RCC, a really uncommon subtype of non-clear cell RCC. We categorize RCC sufferers into clear cell and non-clear cell, and the non-clear cell group consists of very uncommon subtypes. Fumarate hydratase-deficient RCC accounts for about 1% to 2% of all instances. A part 2 trial evaluating Lenvima plus Tevimbra demonstrated a particularly excessive goal response fee, nearly 90%, with 20% of sufferers attaining a whole response, that means no main illness development. All sufferers achieved illness management, and this mix could also be a promising first-line commonplace of care remedy choice for sufferers with fumarate hydratase-deficient RCC.
ctDNA and biomarkers on this remedy discipline are gaining consideration and have been for some time now. What function do these play in kidney most cancers remedy, and may they assist information personalised remedy?
ctDNA is a extremely helpful biomarker in all forms of most cancers. We will use ctDNA for most cancers screening, early most cancers detection, from analysis to the metastatic stage; we will use it at each step through the most cancers course. Quite a few trials and research are ongoing. Nonetheless, we nonetheless want time to make use of it in our medical observe for kidney most cancers sufferers. However we will ask some questions on how we will use ctDNA in our sufferers. The primary query is: Is there any function for ctDNA in small renal plenty, and may we use it to pick sufferers for surgical procedure, different native ablative therapies, or statement? The second query is: Can we use ctDNA to pick sufferers after surgical procedure to offer them adjuvant Keytruda (pembrolizumab)? Adjuvant Keytruda is a typical of care within the adjuvant setting to forestall illness recurrence. So, can we use ctDNA to pick sufferers for adjuvant Keytruda or statement? And the third query is: Can we use ctDNA within the metastatic setting for prognosis or predicting remedy response?
In mild of those questions, there was a trial offered at ASCO GU 2025, the CALYPSO trial. This part 2 trial evaluated the efficacy of Imfinzi (durvalumab), an immune checkpoint inhibitor, plus savolitinib, a c-MET-targeted tyrosine kinase inhibitor, in sufferers with papillary cell RCC. The exploratory evaluation of this trial confirmed that baseline ctDNA and ctDNA clearance have been prognostic, and excessive ctDNA ranges have been related to worse survival outcomes. We’d like additional research and research designs to make use of ctDNA in our every day medical observe for kidney most cancers sufferers.
On the subject of biomarkers, KIM-1, kidney harm molecule-1, is a extremely promising biomarker, and we’re very enthusiastic about it in kidney most cancers. Beforehand, its prognostic function within the metastatic setting and its use for predicting illness recurrence within the adjuvant setting have been proven in numerous research. Now, at ASCO GU 2025, Dr. Wenxin Xu from Dana-Farber Most cancers Institute offered the outcomes of baseline KIM-1 and lowering KIM-1 ranges with remedy within the CHECKMATE-214 trial, involving sufferers receiving the Opdivo plus Yervoy mixture.
Based mostly on the outcomes, if we see a very good response in KIM-1 ranges within the third week of remedy, we will say that the prognosis is sweet with Opdivo plus Yervoy remedy. Nonetheless, if we do not see any response, can we are saying that the prognosis is poor, and will we alter or intensify our remedy with different regimens or combos? The outcomes are promising, however we’d like extra knowledge and potential analysis of those findings in a medical trial to make choices about remedy choice and intensification.
This transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
